Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study.

Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N.

J Int AIDS Soc. 2011 Mar 28;14:16. doi: 10.1186/1758-2652-14-16.

2.

Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M.

J Clin Oncol. 2009 Feb 20;27(6):884-90. doi: 10.1200/JCO.2008.19.6626. Epub 2008 Dec 29.

PMID:
19114688
3.

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

PMID:
15770006
4.

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

AIDS. 2008 Oct 18;22(16):2143-53. doi: 10.1097/QAD.0b013e3283112b77.

5.

Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.

Chiu CG, Smith D, Salters KA, Zhang W, Kanters S, Milan D, Montaner JSG, Coldman A, Hogg RS, Wiseman SM.

BMC Cancer. 2017 Apr 14;17(1):270. doi: 10.1186/s12885-017-3229-1.

6.

Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies.

Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, Bigoloni A, Cinque P, Bossolasco S, Travi G, Fumagalli L, Lazzarin A, Castagna A.

Int J Cancer. 2012 Jun 15;130(12):2990-6. doi: 10.1002/ijc.26332. Epub 2011 Aug 30.

7.

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):931-9.

PMID:
17926647
8.

Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.

Bonnet F, Morlat P, Chêne G, Mercié P, Neau D, Chossat I, Decoin M, Djossou F, Beylot J, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2002 Jul;3(3):195-9.

9.

Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.

Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4).

AIDS. 2014 Sep 10;28(14):2109-18. doi: 10.1097/QAD.0000000000000382.

PMID:
25265077
10.
11.

Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART.

Franzetti M, Adorni F, Parravicini C, Vergani B, Antinori S, Milazzo L, Galli M, Ridolfo AL.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):414-20. doi: 10.1097/QAI.0b013e318282a189.

PMID:
23274934
12.

Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.

Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D.

J Clin Oncol. 2003 Sep 15;21(18):3447-53.

PMID:
12972519
13.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
14.

Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.

Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF.

Cancer. 2005 Oct 1;104(7):1505-11.

15.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
16.

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G; Mortality 2000 study group.

Int J Epidemiol. 2005 Feb;34(1):121-30. Epub 2004 Nov 23.

PMID:
15561752
17.

Cancer risk among participants in the women's interagency HIV study.

Hessol NA, Seaberg EC, Preston-Martin S, Massad LS, Sacks HS, Silver S, Melnick S, Abulafia O, Levine AM; WIHS Collaborative Study Group.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85.

PMID:
15220706
18.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
19.

Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.

Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, Phanuphak P.

Int J Epidemiol. 1998 Apr;27(2):289-95.

PMID:
9602412
20.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648

Supplemental Content

Support Center